Is Bone Biologics Stock a Good Investment?
Bone Biologics Investment Advice | BBLGW |
- Examine Bone Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bone Biologics' leadership team and their track record. Good management can help Bone Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Bone Biologics' business and its evolving consumer preferences.
- Compare Bone Biologics' performance and market position to its competitors. Analyze how Bone Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Bone Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bone Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bone Biologics Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bone Biologics Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bone Biologics Stock
Researching Bone Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.14. Bone Biologics Corp had not issued any dividends in recent years. The entity had 1:30 split on the 7th of June 2023.
To determine if Bone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bone Biologics' research are outlined below:
| Bone Biologics Corp is way too risky over 90 days horizon | |
| Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
| Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (9.56 M) of positive cash flow from operations. | |
| Bone Biologics Corp has a poor financial position based on the latest SEC disclosures |
Bone Biologics' profitablity analysis
Bone Biologics' profitability indicators refer to fundamental financial ratios that showcase Bone Biologics' ability to generate income relative to its revenue or operating costs. If, let's say, Bone Biologics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bone Biologics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bone Biologics' profitability requires more research than a typical breakdown of Bone Biologics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
Determining Bone Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bone Biologics is a good buy. For example, gross profit margin measures Bone Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bone Biologics' profitability and make more informed investment decisions.
The data published in Bone Biologics' official financial statements usually reflect Bone Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bone Biologics Corp. For example, before you start analyzing numbers published by Bone accountants, it's critical to develop an understanding of what Bone Biologics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Bone Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bone Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Please utilize our Beneish M Score to check the likelihood of Bone Biologics' management manipulating its earnings.
Evaluate Bone Biologics' management efficiency
The company has return on total asset (ROA) of (0.9634) % which means that it has lost $0.9634 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0215) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.51 in 2024. Return On Capital Employed is likely to climb to -3.08 in 2024. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2024, whereas Total Assets are likely to drop slightly above 2.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.05 | 11.60 | |
| Net Current Asset Value | -6.4 K | -6.8 K | |
| Tangible Asset Value | -6.4 K | -6.8 K | |
| Tangible Book Value Per Share | 11.05 | 11.60 | |
| Enterprise Value Over EBITDA | 0.19 | 0.20 | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | 0.19 | 0.20 | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | -1.8 M | -1.7 M |
The analysis of Bone Biologics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Bone Biologics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Bone Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.578 |
Basic technical analysis of Bone Stock
As of the 9th of May, Bone Biologics shows the Downside Deviation of 21.42, risk adjusted performance of 0.0815, and Mean Deviation of 10.81. Bone Biologics Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Bone Biologics Corp, which can be compared to its peers. Please confirm Bone Biologics Corp coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bone Biologics Corp is priced correctly, providing market reflects its regular price of 19.01 per share. Given that Bone Biologics has jensen alpha of 2.06, we suggest you to validate Bone Biologics Corp's prevailing market performance to make sure the company can sustain itself at a future point.Bone Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hankey Don over a month ago Acquisition by Hankey Don of 553191 shares of Bone Biologics subject to Rule 16b-3 | ||
Delshad Jim over a month ago Acquisition by Delshad Jim of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | ||
Deina Walsh over a month ago Acquisition by Deina Walsh of 12500 shares of Bone Biologics at 3.61 subject to Rule 16b-3 |
Understand Bone Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bone Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0815 | |||
| Market Risk Adjusted Performance | 1.68 | |||
| Mean Deviation | 10.81 | |||
| Semi Deviation | 11.64 | |||
| Downside Deviation | 21.42 | |||
| Coefficient Of Variation | 862.39 | |||
| Standard Deviation | 18.75 | |||
| Variance | 351.45 | |||
| Information Ratio | 0.1113 | |||
| Jensen Alpha | 2.06 | |||
| Total Risk Alpha | (0.19) | |||
| Sortino Ratio | 0.0974 | |||
| Treynor Ratio | 1.67 | |||
| Maximum Drawdown | 105.47 | |||
| Value At Risk | (24.47) | |||
| Potential Upside | 39.28 | |||
| Downside Variance | 458.8 | |||
| Semi Variance | 135.47 | |||
| Expected Short fall | (20.64) | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.71 |
| Risk Adjusted Performance | 0.0815 | |||
| Market Risk Adjusted Performance | 1.68 | |||
| Mean Deviation | 10.81 | |||
| Semi Deviation | 11.64 | |||
| Downside Deviation | 21.42 | |||
| Coefficient Of Variation | 862.39 | |||
| Standard Deviation | 18.75 | |||
| Variance | 351.45 | |||
| Information Ratio | 0.1113 | |||
| Jensen Alpha | 2.06 | |||
| Total Risk Alpha | (0.19) | |||
| Sortino Ratio | 0.0974 | |||
| Treynor Ratio | 1.67 | |||
| Maximum Drawdown | 105.47 | |||
| Value At Risk | (24.47) | |||
| Potential Upside | 39.28 | |||
| Downside Variance | 458.8 | |||
| Semi Variance | 135.47 | |||
| Expected Short fall | (20.64) | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.71 |
Consider Bone Biologics' intraday indicators
Bone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.8 | |||
| Day Median Price | 19.01 | |||
| Day Typical Price | 19.01 | |||
| Price Action Indicator | (2.39) | |||
| Period Momentum Indicator | (4.78) |
Bone Biologics Corporate Filings
8K | 15th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of March 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 4th of March 2024 Other Reports | ViewVerify | |
| 26th of February 2024 Other Reports | ViewVerify |
Bone Stock media impact
Far too much social signal, news, headlines, and media speculation about Bone Biologics that are available to investors today. That information is available publicly through Bone media outlets and privately through word of mouth or via Bone internal channels. However, regardless of the origin, that massive amount of Bone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bone Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bone Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bone Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bone Biologics alpha.
Bone Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bone Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bone Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda | CoFounder Board | Profile |
How to buy Bone Stock?
To provide specific investment advice or recommendations on Bone Biologics Corp stock, we recommend investors consider the following general factors when evaluating Bone Biologics Corp. This will help you to make an informed decision on whether to include Bone Biologics in one of your diversified portfolios:- Examine Bone Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bone Biologics' leadership team and their track record. Good management can help Bone Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Bone Biologics' business and its evolving consumer preferences.
- Compare Bone Biologics' performance and market position to its competitors. Analyze how Bone Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Bone Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bone Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bone Biologics Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bone Biologics Corp is a good investment.
Already Invested in Bone Biologics Corp?
The danger of trading Bone Biologics Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bone Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bone Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bone Biologics Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Bone Biologics Corp information on this page should be used as a complementary analysis to other Bone Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.14) | Return On Assets (0.96) | Return On Equity (2.02) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bone Biologics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.